What is Zacks Research’s Estimate for JAZZ Q1 Earnings?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Zacks Research lifted their Q1 2027 earnings estimates for Jazz Pharmaceuticals in a research note issued to investors on Monday, February 2nd. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will post earnings of $3.82 per share for the quarter, up from their prior estimate of $3.80. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share.

Other analysts also recently issued reports about the company. Morgan Stanley restated an “overweight” rating and issued a $225.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, November 17th. UBS Group reissued a “neutral” rating and set a $188.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Fourteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $167.29 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. The business’s fifty day moving average price is $168.84 and its two-hundred day moving average price is $144.30. The stock has a market cap of $10.16 billion, a PE ratio of -27.56, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $182.99.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Rick E. Winningham sold 5,500 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total value of $994,730.00. Following the transaction, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. This trade represents a 38.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the transaction, the senior vice president owned 19,508 shares in the company, valued at $3,306,801.08. The trade was a 10.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 123,791 shares of company stock worth $21,991,850. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Horizon Investments LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $1,841,000. Danske Bank A S increased its position in shares of Jazz Pharmaceuticals by 33.3% in the fourth quarter. Danske Bank A S now owns 400 shares of the specialty pharmaceutical company’s stock worth $68,000 after acquiring an additional 100 shares in the last quarter. Innealta Capital LLC purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $236,000. Cardinal Capital Management raised its stake in shares of Jazz Pharmaceuticals by 0.5% in the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after acquiring an additional 66 shares during the period. Finally, Bogart Wealth LLC lifted its holdings in shares of Jazz Pharmaceuticals by 13,650.0% during the 4th quarter. Bogart Wealth LLC now owns 550 shares of the specialty pharmaceutical company’s stock valued at $94,000 after acquiring an additional 546 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.